N-(5-Bromopyrazin-2-yl)pivalamide

Catalog No.: 
ACFLSN157
CAS No.: 
710322-28-4
Molecular Formula: 
C9H12BrN3O
Molecular Weight: 
258.12
N-(5-Bromopyrazin-2-yl)pivalamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$70.00InquiryInquiry
100mg97%$95.00InquiryInquiry
250mg97%$130.00InquiryInquiry
1g97%$242.00InquiryInquiry
5g97%$680.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(5-Bromopyrazin-2-yl)pivalamide
IUPAC NameN-(5-bromopyrazin-2-yl)pivalamide
MDL No.MFCD20882807
Molecular FormulaC9H12BrN3O
Molecular Weight258.12
SMILESCC(C)(C)C(NC1=NC=C(Br)N=C1)=O
InChI KeyHLURXGVOCYJEDG-UHFFFAOYSA-N
SynonymN-(5-Bromo-pyrazin-2-yl)-2,2-dimethyl-propionamide;Propanamide, N-(5-bromo-2-pyrazinyl)-2,2-dimethyl-
CAS No.710322-28-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACFLSN157 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACIMHG586 route compound structure diagram
    ACIMHG58659489-71-3In Stock
  4. Then
  5. ACFLSN157 route product structure diagram
    ACFLSN157710322-28-4
Inquiry

2. ACFLSN157 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCRFX132 route compound structure diagram
    ACCRFX1322964572-05-0In Stock
  2. Plus
  3. ACIMHG586 route compound structure diagram
    ACIMHG58659489-71-3In Stock
  4. Then
  5. ACFLSN157 route product structure diagram
    ACFLSN157710322-28-4
Inquiry

3. ACFLSN157 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFLSN157 route product structure diagram
    ACFLSN157710322-28-4
Inquiry

Comments (0)